Exclusive: Biogen leaders warn sales teams: Only 2,000 patients might access Aduhelm over the next several years
Biogen execs on Thursday tried to level with their Aduhelm sales staff and prep for a 28-day blitz to convince CMS to reverse or loosen …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
